124 related articles for article (PubMed ID: 37595020)
21. Crystallization of Nuclear Export Signals or Small-Molecule Inhibitors Bound to Nuclear Exporter CRM1.
Fung HYJ; Chook YM
Methods Mol Biol; 2022; 2502():285-297. PubMed ID: 35412246
[TBL] [Abstract][Full Text] [Related]
22. The past, present, and future of CRM1/XPO1 inhibitors.
Wang AY; Liu H
Stem Cell Investig; 2019; 6():6. PubMed ID: 30976603
[TBL] [Abstract][Full Text] [Related]
23. The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates.
Klahn P; Fetz V; Ritter A; Collisi W; Hinkelmann B; Arnold T; Tegge W; Rox K; Hüttel S; Mohr KI; Wink J; Stadler M; Wissing J; Jänsch L; Brönstrup M
Chem Sci; 2019 May; 10(20):5197-5210. PubMed ID: 31191875
[TBL] [Abstract][Full Text] [Related]
24. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
25. Correlation of CRM1-NES affinity with nuclear export activity.
Fu SC; Fung HYJ; Cağatay T; Baumhardt J; Chook YM
Mol Biol Cell; 2018 Aug; 29(17):2037-2044. PubMed ID: 29927350
[TBL] [Abstract][Full Text] [Related]
26. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
[TBL] [Abstract][Full Text] [Related]
27. Atomic basis of CRM1-cargo recognition, release and inhibition.
Fung HY; Chook YM
Semin Cancer Biol; 2014 Aug; 27():52-61. PubMed ID: 24631835
[TBL] [Abstract][Full Text] [Related]
28. KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib.
Nie D; Huang K; Yin S; Li Y; Xie S; Ma L; Wang X; Wu Y; Xiao J; Wang J; Yang W; Liu H
Cell Death Discov; 2018; 4():48. PubMed ID: 29707241
[TBL] [Abstract][Full Text] [Related]
29. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
30. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract][Full Text] [Related]
31. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
32. Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Sui M; Xiong M; Li Y; Zhou Q; Shen X; Jia D; Gou M; Sun Q
Int J Nanomedicine; 2021; 16():2833-2847. PubMed ID: 33883894
[TBL] [Abstract][Full Text] [Related]
33. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
34. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
35. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.
Zhang K; Wang M; Tamayo AT; Shacham S; Kauffman M; Lee J; Zhang L; Ou Z; Li C; Sun L; Ford RJ; Pham LV
Exp Hematol; 2013 Jan; 41(1):67-78.e4. PubMed ID: 22986101
[TBL] [Abstract][Full Text] [Related]
36. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.
Cheng Y; Holloway MP; Nguyen K; McCauley D; Landesman Y; Kauffman MG; Shacham S; Altura RA
Mol Cancer Ther; 2014 Mar; 13(3):675-86. PubMed ID: 24431073
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
[TBL] [Abstract][Full Text] [Related]
38. A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.
Tajiri N; De La Peña I; Acosta SA; Kaneko Y; Tamir S; Landesman Y; Carlson R; Shacham S; Borlongan CV
CNS Neurosci Ther; 2016 Apr; 22(4):306-15. PubMed ID: 26842647
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
Parikh K; Cang S; Sekhri A; Liu D
J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
[TBL] [Abstract][Full Text] [Related]
40. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
